Journal
ENDOCRINE PRACTICE
Volume 18, Issue 2, Pages 132-139Publisher
AMER ASSOC CLINICAL ENDOCRINOLOGISTS
DOI: 10.4158/EP11131.OR
Keywords
-
Categories
Ask authors/readers for more resources
Objective: To study the association of vitamin D receptor (VDR) gene polymorphisms (BsmI, ApaI, and TaqI) with susceptibility to Graves disease (GD) in Egyptian patients and their correlation with serum levels of I,25-dihydroxyvitamin D-3 [1,25(OH)2D3]. Methods: The current study consisted of 90 patients with GD (65 women and 25 men), with ages ranging from 25 to 55 years. A control group of 55 healthy euthyroid subjects (40 women and 15 men) with matched ages were included in the study. Genotyping was performed by restriction fragment length polymorphism analysis. Serum levels of 1,25(OH)2D3 were measured with use of radioimmunoassay in the patients and the control subjects. Results: The distribution of genotype frequencies differed significantly between patients with GD and control subjects (BsmI: chi(2) = 10.627, P = .004; ApaI: chi(2) = 12.581, P = .001; TaqI: chi(2) = 9.591, P = .008). We found overexpression of the VDR BsmI bb (odds ratio, 2.360; 95% confidence interval [CI], 1.11 to 4.996), ApaI aa (odds ratio, 2.785; 95% CI, 1.116 to 6.933), and TaqI TT (odds ratio, 3.047; 95% CI, 1.478 to 6.283) genotypes in patients with GD in comparison with control subjects. In contrast, no correlation was observed with respect to the 1,25(OH)2D3 levels with BsmI, ApaI, and TaqI genotypes (P >.05) on the analysis of variance test. Conclusion: These data suggested that BsmI, ApaI, and TaqI polymorphisms in the VDR gene were associated with susceptibility to GD, whereas BsmI, ApaI, and TaqI polymorphisms were not associated with serum levels of 1,25(OH)2D3. (Endocr Pract. 2012;18:132-139)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available